Dr. Itzchak Angel, CEO of the Israeli stem cell company, Accellta, has more than 30 years of experience guiding the business development efforts of new and established companies across the Israeli pharmaceutical industry. Dr. Angel was formerly Vice President of R&D at Proteologics Ltd. and at D-Pharm Biopharmaceuticals. Before those positions, he served as the head of pharmacology in Synthelabo (now Sanofi) where he launched blockbuster drugs such as Xatral, Ambien and Mizollen into the marketplace. [Read more…]
Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).
Within the cord blood industry, there was a strong growth period during the 2000’s. However, over the past few years, the market has substantially matured and consolidated. While strong industry growth continues within North Asia (particularly China, Hong Kong, and Taiwan) and Southeast Asia (led by India and Malaysia), growth of the North American market is flat and the European cord blood banking market is declining. [Read more…]
This is an exciting addition to my recent interview with Accellta’s CEO, Dr. Itzchak Angel, who highlighted Accellta’s unique technologies for enabling large scale growth of cells in suspension. This interview features insights from Eran Cohen, Accellta’s head of business development and intellectual property (IP) officer.
This article identifies four key processing technologies that are utilized by cord blood banks worldwide and the companies responsible for developing each one.
Automated processing systems have many benefits, including speed, processing efficiency, and cost-savings.
However, automated processing systems have not always dominated the cord blood banking industry. [Read more…]
Dental stem cell companies preserve dental pulp, because the stem cells contained within it may be valuable for future medical use. Dental pulp is the soft living tissue inside a tooth that contains mesenchymal stem cells (MSCs).
The ideal time to harvest dental stem cells is when children lose their deciduous (baby) teeth, either through natural loss or extraction.
While MSCs from dental pulp stem cells are only used only in laboratory settings at this time, there are a handful of companies that offer dental stem cell storage services. Currently, the dental storage market is small, because of the early stage of research concerning the use of dental pulp stem cells in humans. [Read more…]